Argenx
ARGX
#527
Rank
NZ$76.14 B
Marketcap
NZ$1,230
Share price
-1.76%
Change (1 day)
22.72%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): NZ$15.24

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$14.96. In 2024 the company made an earnings per share (EPS) of NZ$23.47 an increase over its 2023 EPS that were of NZ-$8.70.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$15.24-35.07%
2024NZ$23.47-369.77%
2023NZ-$8.70-60.46%
2022NZ-$22.0063.33%
2021NZ-$13.47-40.37%
2020NZ-$22.59183.47%
2019NZ-$7.97123.09%
2018NZ-$3.5754.93%
2017NZ-$2.3114.07%
2016NZ-$2.0213.05%
2015NZ-$1.79-36.34%
2014NZ-$2.81209.04%
2013NZ-$0.91-33.99%
2012NZ-$1.38185.59%
2011NZ-$0.48